ProPhase Labs, Inc. (PRPH) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
N/A
—
5yr avg: 0.56
30Y Low0.2·High18.3
P/FCF
N/A
—
5yr avg: 0.36
30Y Low0.4·High53.7
P/B Ratio
↑
0.18
↓-44% vs avg
5yr avg: 0.32
30Y Low0.1·High18.4
ROE
↓
-271.5%
↑-208% vs avg
5yr avg: -88.2%
30Y Low-271%·High221%
Debt/EBITDA
↓
N/A
—
5yr avg: 0.63
30Y Low0.2·High3.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRPH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ProPhase Labs, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $355276 | $4M | $1M | $4M | $9M | $7M | $5M | $5M | $7M | $7M | $7M |
| Enterprise Value | $9M | $12M | $25M | $21M | $7M | $13M | $13M | $4M | $6M | $4M | $8M |
| P/E Ratio → | -0.04 | — | — | — | 0.47 | 0.90 | — | — | — | 0.17 | — |
| P/S Ratio | 0.08 | 0.88 | 0.21 | 0.09 | 0.07 | 0.08 | 0.37 | 0.46 | 0.55 | 0.69 | 0.33 |
| P/B Ratio | 0.18 | 1.09 | 0.20 | 0.08 | 0.14 | 0.11 | 0.50 | 0.41 | 0.44 | 0.21 | 1.15 |
| P/FCF | — | — | — | — | 0.36 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 0.31 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRPH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.84 | 3.74 | 0.47 | 0.06 | 0.16 | 0.91 | 0.42 | 0.43 | 0.37 | 0.38 |
| EV / EBITDA | — | — | — | — | 0.24 | 0.87 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 0.29 | 1.99 | — | — | — | — | — |
| EV / FCF | — | — | — | — | 0.28 | — | — | — | — | — | — |
PRPH Profitability
Margins and return-on-capital ratios measuring operating efficiency
ProPhase Labs, Inc. earns an operating margin of -415.4%. Operating margins have compressed from -48.7% to -415.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -271.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.9% | 31.9% | -2.2% | 36.6% | 57.6% | 41.5% | 31.7% | 26.5% | 36.4% | 19.7% | 47.9% |
| Operating Margin | -415.4% | -415.4% | -570.6% | -48.7% | 19.2% | 12.4% | -27.4% | -32.8% | -12.4% | -40.4% | -12.6% |
| Net Profit Margin | -339.3% | -339.3% | -788.2% | -37.8% | 15.1% | 7.9% | -14.6% | -31.9% | -13.3% | 423.9% | -13.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -271.5% | -271.5% | -188.1% | -29.7% | 30.2% | 18.1% | -19.5% | -22.7% | -7.2% | 221.3% | -38.8% |
| ROA | -24.0% | -24.0% | -68.8% | -18.7% | 20.9% | 10.4% | -9.7% | -19.1% | -6.3% | 178.1% | -20.8% |
| ROIC | -62.5% | -62.5% | -59.4% | -25.4% | 28.0% | 17.6% | -20.4% | -18.9% | -5.6% | -16.8% | -25.5% |
| ROCE | -95.3% | -95.3% | -75.6% | -30.3% | 32.5% | 19.8% | -21.8% | -23.3% | -6.7% | -20.8% | -32.7% |
PRPH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $9M ($9M total debt minus $90000 cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.46 | 2.46 | 3.34 | 0.37 | 0.11 | 0.25 | 1.39 | — | — | — | 0.25 |
| Debt / EBITDA | — | — | — | — | 0.24 | 1.01 | — | — | — | — | — |
| Net Debt / Equity | — | 2.43 | 3.25 | 0.34 | -0.03 | 0.11 | 0.75 | -0.04 | -0.09 | -0.10 | 0.18 |
| Net Debt / EBITDA | — | — | — | — | -0.07 | 0.42 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -0.09 | — | — | — | — | — | — |
| Interest Coverage | -2.37 | -2.37 | -11.64 | -16.88 | 30.98 | 5.62 | -6.84 | — | — | -73.89 | -17.81 |
PRPH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.06x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.28x to 0.06x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.06 | 0.06 | 0.95 | 2.28 | 3.78 | 3.95 | 2.52 | 10.66 | 4.31 | 15.96 | 1.41 |
| Quick Ratio | 0.06 | 0.06 | 0.92 | 2.17 | 3.54 | 3.65 | 2.04 | 9.10 | 3.86 | 15.11 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.02 | 0.23 | 1.08 | 1.13 | 1.34 | 1.46 | 1.95 | 12.11 | 0.06 |
| Asset Turnover | — | 0.07 | 0.11 | 0.48 | 1.40 | 0.89 | 0.46 | 0.80 | 0.63 | 0.29 | 1.64 |
| Inventory Turnover | 42.30 | 42.30 | 6.05 | 12.29 | 13.08 | 10.05 | 3.26 | 4.98 | 4.39 | 5.17 | 4.00 |
| Days Sales Outstanding | — | 129.03 | 1081.41 | 294.52 | 110.27 | 174.13 | 79.34 | 252.13 | 216.84 | 71.95 | 100.22 |
PRPH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ProPhase Labs, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 100.0% | 68.8% | — | 100.0% | 100.0% | — | — |
| Payout Ratio | — | — | — | — | 50.7% | 72.5% | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 211.6% | 111.4% | — | — | — | 596.8% | — |
| FCF Yield | — | — | — | — | 274.0% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 13.9% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 82.7% | 0.0% | 100.0% | 100.0% | 100.0% | 0.0% |
| Shares Outstanding | — | $8M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $2M | $2M |
Peer Comparison
Compare PRPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRPHYou | $355276 | -0.0 | — | — | 31.9% | -415.4% | -271.5% | -62.5% | — |
 QDEL | $931M | -0.8 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 CLOV | $3B | -29.4 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 BNGO | $4M | -0.2 | — | — | 22.0% | -116.9% | -66.2% | -49.1% | — |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 FLGT | $535M | -9.1 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 CERS | $541M | -32.9 | — | 63.5 | 53.5% | -17.6% | -25.6% | -19.7% | — |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 A | $36B | 27.8 | 21.2 | 31.2 | 52.4% | 21.3% | 20.6% | 13.5% | 1.9 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PRPH — Frequently Asked Questions
Quick answers to the most common questions about buying PRPH stock.
What is ProPhase Labs, Inc.'s P/E ratio?
ProPhase Labs, Inc.'s current P/E ratio is -0.0x. The historical average is 15.0x.
What is ProPhase Labs, Inc.'s ROE?
ProPhase Labs, Inc.'s return on equity (ROE) is -271.5%. The historical average is -17.5%.
Is PRPH stock overvalued?
Based on historical data, ProPhase Labs, Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
What are ProPhase Labs, Inc.'s profit margins?
ProPhase Labs, Inc. has 31.9% gross margin and -415.4% operating margin.